Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...
Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...
A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...
With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...
A study confirmed that side effects like pancreatitis and kidney damage are possible while taking GLP-1s like Ozempic. Here's ...
Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback